An ESR1 evaluation
September 2020

COLUMBUS, Ohio—A new collaboration is underway between Sermonix Pharmaceuticals Inc. and Eli Lilly and Co. to evaluate a combination regimen of Sermonix’s lead candidate lasofoxifene and Lilly’s abemaciclib, an FDA-approved CDK 4 and 6 inhibitor. The companies will conduct ELAINE2, an open-label, multi-center Phase 2 clinical trial to evaluate the safety of the combination in pre- and postmenopausal women with locally advanced metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer and an ESR1 mutation.
“Endocrine therapy is the backbone of combination therapies in ER+/HER2- breast cancer, and as a well-characterized compound, lasofoxifene may offer patients a potentially well-tolerated oral option alone and in combination in an area of significant unmet need,” said Sermonix Board Chairman Dr. Anthony Wild. “We look forward to embarking on ELAINE 2 and executing on this important trial.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.